Biotech News
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of Medicine Anticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S. launch in first half of 2027 Enrollment successfully reinitiated in nex-z Phase 3 clinical trials;